IL208992A - Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure - Google Patents

Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure

Info

Publication number
IL208992A
IL208992A IL208992A IL20899210A IL208992A IL 208992 A IL208992 A IL 208992A IL 208992 A IL208992 A IL 208992A IL 20899210 A IL20899210 A IL 20899210A IL 208992 A IL208992 A IL 208992A
Authority
IL
Israel
Prior art keywords
heart failure
acute
relaxin
medicaments
manufacture
Prior art date
Application number
IL208992A
Other languages
English (en)
Hebrew (he)
Other versions
IL208992A0 (en
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of IL208992A0 publication Critical patent/IL208992A0/en
Publication of IL208992A publication Critical patent/IL208992A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL208992A 2008-05-16 2010-10-28 Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure IL208992A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
PCT/US2009/044249 WO2009140659A2 (en) 2008-05-16 2009-05-15 Method of treating dyspnea associated with acute heart failure

Publications (2)

Publication Number Publication Date
IL208992A0 IL208992A0 (en) 2011-01-31
IL208992A true IL208992A (en) 2013-09-30

Family

ID=40834101

Family Applications (3)

Application Number Title Priority Date Filing Date
IL208992A IL208992A (en) 2008-05-16 2010-10-28 Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure
IL228244A IL228244A (en) 2008-05-16 2013-09-02 2h Active Relaxin Human Pharmacist for Use as a Medication to Treat Severe Heart Failure
IL247351A IL247351A0 (en) 2008-05-16 2016-08-18 A pharmaceutically active human H2 relaxin for use as a drug in the treatment of dyspnea associated with severe heart failure

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL228244A IL228244A (en) 2008-05-16 2013-09-02 2h Active Relaxin Human Pharmacist for Use as a Medication to Treat Severe Heart Failure
IL247351A IL247351A0 (en) 2008-05-16 2016-08-18 A pharmaceutically active human H2 relaxin for use as a drug in the treatment of dyspnea associated with severe heart failure

Country Status (30)

Country Link
US (7) US8053411B2 (OSRAM)
EP (2) EP2829280A1 (OSRAM)
JP (4) JP5651586B2 (OSRAM)
CN (3) CN102036679A (OSRAM)
AR (1) AR071810A1 (OSRAM)
AU (1) AU2009246114B2 (OSRAM)
BR (1) BRPI0913011A2 (OSRAM)
CA (1) CA2724540C (OSRAM)
CR (1) CR11749A (OSRAM)
CY (1) CY1116925T1 (OSRAM)
DK (1) DK2288373T3 (OSRAM)
EA (2) EA022948B1 (OSRAM)
ES (1) ES2546287T3 (OSRAM)
GB (2) GB2462221B (OSRAM)
HK (1) HK1202054A1 (OSRAM)
HR (1) HRP20150845T1 (OSRAM)
HU (1) HUE025483T2 (OSRAM)
IL (3) IL208992A (OSRAM)
MA (1) MA32389B1 (OSRAM)
MX (1) MX2010012450A (OSRAM)
MY (2) MY159803A (OSRAM)
NZ (3) NZ589009A (OSRAM)
PL (1) PL2288373T3 (OSRAM)
PT (1) PT2288373E (OSRAM)
SG (2) SG10201609580YA (OSRAM)
SI (1) SI2288373T1 (OSRAM)
TW (1) TWI386202B (OSRAM)
UA (1) UA99953C2 (OSRAM)
WO (1) WO2009140659A2 (OSRAM)
ZA (1) ZA201007449B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246112B2 (en) * 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX2012010382A (es) * 2010-03-10 2013-01-29 Univ Melbourne Modulacion de acuaporinas con relaxina.
US8501418B2 (en) * 2010-08-06 2013-08-06 Pronata N.V. Method of treating renal dysfunction based on perlecan as a biomarker
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2742296T3 (es) * 2010-08-17 2020-02-13 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
KR102107482B1 (ko) * 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
KR102299073B1 (ko) 2012-10-26 2021-09-09 치에시 파마슈티시 에스.피.아. 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
AU2020214314B2 (en) 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
EP4580653A1 (en) 2022-08-31 2025-07-09 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
EP0675732B1 (en) * 1993-07-27 2006-06-28 Mario Bigazzi Use of relaxin in the manufacture of therapeutic agents
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
EP0845992B1 (en) 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
CA2397200C (en) * 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US20070202080A1 (en) 2004-03-30 2007-08-30 Industry-University Cooperation Foundation Yonsei Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
WO2007008907A2 (en) 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
JP5355561B2 (ja) 2007-07-12 2013-11-27 コンピュゲン エルティーディー． 生物活性ペプチドおよびその使用方法
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
AU2009246112B2 (en) 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure

Also Published As

Publication number Publication date
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US20120040902A1 (en) 2012-02-16
MY158327A (en) 2016-09-30
CN102036679A (zh) 2011-04-27
US20130210730A1 (en) 2013-08-15
JP5651586B2 (ja) 2015-01-14
JP2011520918A (ja) 2011-07-21
HUE025483T2 (en) 2016-02-29
CR11749A (es) 2011-02-11
NZ701038A (en) 2016-01-29
TWI386202B (zh) 2013-02-21
US20170151311A1 (en) 2017-06-01
AU2009246114B2 (en) 2013-01-31
CN106177914A (zh) 2016-12-07
JP2016053040A (ja) 2016-04-14
HK1202054A1 (en) 2015-09-18
UA99953C2 (uk) 2012-10-25
JP5875646B2 (ja) 2016-03-02
US20100048475A1 (en) 2010-02-25
EA201001771A1 (ru) 2011-06-30
NZ598709A (en) 2013-09-27
US20150320834A1 (en) 2015-11-12
AR071810A1 (es) 2010-07-14
GB2459983B (en) 2010-04-28
CA2724540C (en) 2014-07-08
MX2010012450A (es) 2011-03-21
JP2015013870A (ja) 2015-01-22
JP5638044B2 (ja) 2014-12-10
WO2009140659A2 (en) 2009-11-19
WO2009140659A3 (en) 2010-07-22
TW200948353A (en) 2009-12-01
GB0918132D0 (en) 2009-12-02
GB2459983A (en) 2009-11-18
MY159803A (en) 2017-02-15
SG10201609580YA (en) 2016-12-29
DK2288373T3 (en) 2015-09-28
HK1187550A1 (zh) 2014-04-11
BRPI0913011A2 (pt) 2019-09-03
AU2009246114A1 (en) 2009-11-19
EP2288373A2 (en) 2011-03-02
JP2013040174A (ja) 2013-02-28
PL2288373T3 (pl) 2015-11-30
EA022948B1 (ru) 2016-03-31
US8053411B2 (en) 2011-11-08
CN103212063A (zh) 2013-07-24
ZA201007449B (en) 2011-06-29
HK1151229A1 (en) 2012-01-27
US8415301B2 (en) 2013-04-09
US20130116181A1 (en) 2013-05-09
US9579363B2 (en) 2017-02-28
US20120040903A1 (en) 2012-02-16
HK1139051A1 (en) 2010-09-10
CN103212063B (zh) 2015-07-22
US8372809B2 (en) 2013-02-12
EA201500552A1 (ru) 2016-07-29
CY1116925T1 (el) 2017-04-05
SI2288373T1 (sl) 2015-12-31
SG191587A1 (en) 2013-07-31
US9205132B2 (en) 2015-12-08
EP2829280A1 (en) 2015-01-28
ES2546287T3 (es) 2015-09-22
IL247351A0 (en) 2016-09-29
HRP20150845T1 (hr) 2015-11-06
PT2288373E (pt) 2015-10-19
IL208992A0 (en) 2011-01-31
CA2724540A1 (en) 2009-11-19
GB2462221A (en) 2010-02-03
EP2288373B1 (en) 2015-06-24
IL228244A (en) 2016-10-31
US9066916B2 (en) 2015-06-30
GB0908432D0 (en) 2009-06-24
GB2462221B (en) 2010-09-01
HK1140693A1 (en) 2010-10-22

Similar Documents

Publication Publication Date Title
IL208992A (en) Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
WO2011011642A3 (en) Biphasic and dynamic adjustable support devices and methods with assist and recoil capabilities for treatment of cardiac pathologies
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
MX2010008433A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares.
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
MD3987C2 (ro) Utilizare a Diosminei pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă
Reynolds Cardiac resynchronization for heart failure: Its time has come
NZ622598A (en) Treating acute decompensated heart failure with relaxin
UA40165U (ru) Способ оценки уровня кортизола у больных с ишемической болезнью сердца
UA40164U (ru) Способ оценки активности антиоксидантной системы у больных хронической сердечной недостаточностью
NZ625344A (en) Treatment of heart failure with normal ejection fraction
Orynchak et al. Correction of hemodynamic by telmisartan and torasemid in hypertensives with heart failure and hyperinsulinemia: P708
UA43076U (ru) Способ диагностики ишемических поражений сердца при нейрометамерной патологии
UA46804U (ru) Способ оценки уровня вазопрессина при хронической сердечной недостаточности
UA56368U (ru) способ лечения больных хронической сердечной недостаточностью коронарогенного генеза с сопутствующей анемией
UA33149U (ru) Способ лечения аритмий у пациентов с малыми структурными аномалиями сердца
UA41944U (ru) Способ прогнозирования выживания больных с хронической сердечной недостаточностью та систолической дисфункцией левого желудочка
MD3986C2 (ro) Utilizare a Diosminei pentru tratamentul gastropatiilor portale în ciroza hepatică

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees